Literature DB >> 1964600

Incidence of herpes simplex virus type-1 and type-2 from patients with primary (first-attack) genital herpes in Sheffield.

P D Woolley1, G Kudesia.   

Abstract

In a study to determine the herpes simplex virus (HSV) type isolated from patients with primary (first-attack) genital herpes and to identify any clinical or epidemiological features that might influence the reported incidence of any particular viral type, there was almost an equal incidence of HSV-1 and HSV-2 isolated from women (48% versus 52%). In the case of women, the initial clinical diagnosis was correct in 97% with HSV-1 and 95% with HSV-2 infection. Amongst men, HSV-2 was isolated more frequently than HSV-1 (71% versus 29%). However, the initial clinical diagnosis in men was correct in only 53% with HSV-1 and 83% with HSV-2 infection. These results suggest that in primary genital herpes the incidence of HSV-1 and HSV-2 is probably equal, while in men the reported incidence of HSV-1 may be affected by underdiagnosis giving a falsely high incidence of HSV-2 infection.

Entities:  

Mesh:

Year:  1990        PMID: 1964600     DOI: 10.1177/095646249000100306

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  4 in total

1.  Genital herpes.

Authors:  A M Geretti
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

Review 2.  Oral sex and the transmission of viral STIs.

Authors:  S Edwards; C Carne
Journal:  Sex Transm Infect       Date:  1998-02       Impact factor: 3.519

Review 3.  Recent advances in management of genital herpes.

Authors:  I Tétrault; G Boivin
Journal:  Can Fam Physician       Date:  2000-08       Impact factor: 3.275

4.  First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology.

Authors:  G B Löwhagen; P Tunbäck; K Andersson; T Bergström; G Johannisson
Journal:  Sex Transm Infect       Date:  2000-06       Impact factor: 3.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.